1 / 4

UK Oncolytic Virus Therapy Market Size, Share and Forecast 2019-2025

UK Oncolytic Virus Therapy Market by Product (HSV-Based Oncolytic Viruses, Adenoviruses-Based Oncolytic Viruses, Vaccinia Virus-Based Oncolytic Viruses, Vesicular Stomatitis Virus-Based Oncolytic Viruses, Newcastle Disease Oncolytic Viruses, and Others), By Application (Prostate Cancer, Breast Cancer, Ovarian Cancer, Melanoma, and Others), and Forecast 2019-2025

larebomrglobal
Download Presentation

UK Oncolytic Virus Therapy Market Size, Share and Forecast 2019-2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research UK Oncolytic Virus Therapy Market: Industry Growth, Size, Share and Forecast 2019-2025 Request https://www.omrglobal.com/request-sample/uk-oncolytic-virus-therapy-market ------------------------------------------------------------------------------------ a Free Report on Sample of UK Oncolytic Virus Therapy Market @ Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 7803040404

  2. The UK oncolytic virus therapy market is estimated to grow at a CAGR of more than 13% during the forecast period. Research in the field of Oncolytic virus is still in its initial phase in UK. A second-generation oncolytic virus-based drug is registered in UK under the name of talimogene laherparepvec. Amgen Inc, Merck & Co., Inc. and Experimental Cancer Medicine Centre (ECMC) are few of the key organizations which are investing in the clinical trials involving oncolytic virus therapy in UK in collaboration with Cancer Research UK. In line with the strategy of developing treatment alternatives, the companies have introduced various clinical trials including the effect of talimogene laherparepvec on melanoma and head and neck cancers. A full Report of UK Oncolytic Virus Therapy Market at https://www.omrglobal.com/industry- reports/uk-oncolytic-virus-therapy-market The UK oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share of over 94% in 2018, whereas, adenoviruses-based therapy held the rest. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share. Request a Free Report on Sample of https://www.omrglobal.com/request-sample/uk-oncolytic-virus-therapy-market The report covers the analysis of several players such as Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Medigene AG, Merck and Co. Inc., Amgen Inc., Orca Therapeutics, OncoTheis, and others operating in the UK oncolytic virus therapy market. PsiOxus Therapeutics Ltd. is one of the companies headquartered in UK. The company is collaborating with other immuno-oncology companies in the market for the purpose of increasing their consumer base. In December 2017, the application for the clinical trial of NG-348 for the treatment of solid tumor was approved. For this, the Bristol Myers Squibb has paid $15 million to PsiOxus as a per the licensing agreement between the two firms. The two companies entered into strategic collaboration on Dec 2016, in which Bristol Myers granted $50 million to PsiOxus. UK Oncolytic Virus Therapy Market Segmentation By Product HSV-Based Oncolytic Virus Adenoviruses-Based Oncolytic Virus Vaccinia Virus-Based Oncolytic Virus Vesicular Stomatitis Virus-Based Oncolytic Virus UK Oncolytic Virus Therapy Market @

  3. Newcastle Disease Virus- Based Oncolytic Virus Others By Application Prostate Cancer Breast Cancer Ovarian Cancer Melanoma Others Regional Analysis US Canada Company Profiles AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company Cold Genesys Inc. Creative Biolabs Inc. Cynvec LLC DNAtrix Inc. Genelux Corp. Janssen Biotech Inc. Merck & Co., Inc. Oncolytic Biotech, Inc. Oncorus Inc. Sorrento Therapeutics Inc. Vyriad For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report- customization/uk-oncolytic-virus-therapy-market

  4. About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research- based services. For More Information, Visit Orion Market Research Media Contact: Company Name: Orion Market Research Contact Person: Mr. AnuragTiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 780-304-0404 Visit for Global Oncolytic Virus Therapy Market

More Related